Considering the significant SARS-CoV-2 related risk factors for hospitalization and mortality among patients with metabolic diseases, including obesity, arterial hypertension, cardiovascular diseases, and diabetes that may reflect overall activation of the RAS system, modulation of RAS activation through the ACE2/(Ang1-7)/MAS pathway should be considered for treatment of this disease. This evidence concerns the gene ACE2 and diabetes mellitus.